In the contest of COVID-19 rapid spread in Italy, the Italian Government in March 2020 released an official recommendation statement indicating [@b0005].

Regarding oncological patients, the statement indicates to regional health authorities to identify and implement as quickly as possible the arrangements necessary to ensure oncological treatments, in order not to influence disease prognosis.

The Italian Association of Radiotherapy and Clinical Oncology (AIRO) released an orientation paper in order to assure homogeneous working procedures during the COVID-19 pandemic emergency [@b0010].

Interventional Radiation Therapy (IRT, Brachytherapy, BT) and IntraOperative Radiotherapy (IORT) represent potentially life-saving treatment options in different oncological clinical settings with indications shared in multidisciplinary contexts following international guidelines or trial protocols [@b0015]. Delaying radiation treatments could worsen the overall prognosis of the disease, so that it seems to be essential to ensure radiation treatments delivery even at the time of COVID-19 emergency, fully guaranteeing health professionals, patients, and caregivers safety [@b0020], [@b0025].

Current evidences review on "COVID-19 disease" and "Radiation Oncology" was performed, then a multicenter team composed by all members of current AIRO-IRT/IORT-Working Group (WG), an infectious disease expert working in a COVID-19 Hospital, the past chair and deputy chair of AIRO-IRT/IORT-WG, members of AIRO committee, the chair of the Scientific Committee and the president of AIRO wrote this document.

To enable the regular conduct of clinical activity and the reduction of the risk of COVID-19 diffusion in the radiation oncology departments, it is essential to identify patients and operators with suspected or proven infection performing triage at the hospital and/or departments entrance ([Table 1](#t0005){ref-type="table"} ).Table 1Suspected or positive COVID-19 patient management in Radiation Oncology Departments.TriageGeneral recommendationsRadiation treatment recommendations[Patient at home]{.ul}Physiological anamnesis through telephone or videoconference contact in order to limit suspicious patient access to Radiation Oncology Departments\
Consider link suspicious patients to Local Public Health Institution Agency or General practitioner for domiciliary COVID-19 screeningPostpone and/or convert follow-up evaluations to telephone/videoconference contact in case of negative COVID-19 patients without referred post-treatment symptoms\
Plan follow-up evaluations in COVID-19 negative patients but with referred symptoms related to radiation treatments according to the clinical case presentation verified telephone/videoconference contact[Asymptomatic patient]{.ul}Imperative wearing of mask (according to internal recommendation).\
Assure recommended inter-personal distance\
Body temperature check at Department main entrance\
Physiological anamnesis and patient self-declaration of health.\
Consider COVID-19 testing for inpatient treatments (according to internal recommendation)Follow treatment program\
Healthcare workers wear surgical mask and follow hands hygiene protocols[Suspicious patient]{.ul} with typical symptoms (cough and/or fever and/or dyspnea and/or conjunctivitis unrelated to oncological disease)Imperative wearing of mask (according to internal recommendation).\
Assure recommended inter-personal distance\
Address patient the hospital dedicated COVID-19 way\
Official notification to Institutional Direction\
Consider COVID-19 testing\
Investigate contact with COVID-19 positive or suspected peoplePostpone the start or interrupt ongoing treatments according to personalized clinical judgment\
If treatment cannot be postponed, assure the respect of local protocols for the Infection Control in patients with COVID-19 or suspected COVID-19\
Healthcare workers wear surgical mask and follow hands hygiene protocols[COVID-19 +]{.ul} patient (symptomatic or asymptomatic)Imperative wearing of mask (according to internal recommendation).\
Assure recommended inter-personal distance\
Address patient the hospital dedicated COVID-19 way\
Official notification to Institutional Direction\
Consider COVID-19 testing\
Investigate contact with COVID-19 positive or suspected people\
Consider symptoms-based hospitalizationPostpone the start or interrupt ongoing treatments according to personalized clinical judgment\
Healthcare workers wear surgical mask (consider FFP2/FFP3 in case of aereosol-generating procedures) and follow hands hygiene protocols[Previous COVID19+]{.ul} patient confirmed healedImperative wearing of mask (according to internal recommendation).\
Assure recommended inter-personal distance\
Consider quarantine with ward and referent cliniciansStart or continue ongoing treatment\
Healthcare workers wear surgical mask and follow hands hygiene protocols

It is strongly recommended the identification of dedicated team members to manage COVID-19 cases. As a general rule, the RADS (Remote visits, Avoidance of treatment if little to no benefit or if an alternative treatment is available, Deferment of treatment if clinically appropriate, and Shortening of radiotherapy if treatment is unavoidable) principle is recommended to plan each individual patient treatment [@b0030].

For new outpatients' appointments it is recommended, if possible, to contact patients the day before the start of treatment (or any fraction if once weekly) whereas any new patient who has to undergo inpatient therapy should be contacted the day before hospitalization or any preoperative anesthesiologic assessment. According to national, regional or institutional recommendation, consider nasopharyngeal swab for SARS-CoV-2 in people who has to undergo inpatient therapy.

In case of suspected or positive patients, starting or continuing treatments should be allowed by local health authorities and carried out under condition of maximum safety for health professionals, with dedicated routes and facilities, dedicated treatment schedules and appropriate sanitization of treatment areas and equipment [@b0035].

It is also recommended to limit access to patients and their relatives or accompanying persons:--offering IRT or IORT, if available and whenever possible,--encouraging high hypofractionation, where indicated,--postponing treatments of certain oncological diseases according to clinical judgement,--in palliative setting it might be useful to optimize medical symptomatic treatments, if judged to be of similar efficacy,--postponing treatment for benign diseases,--considering hormonal or cytotoxic therapy in selected cases for further deferral of radiotherapy,--allowing only one accompanying person per patient, whenever possible,--considering dedicated "COVID+ interventional radiotherapy pathway".

Follow-up evaluations should be:--postponed until proven healing in COVID-19 positive patients,--postponed and/or converted to telephone contact in case of negative COVID-19 patients without referred post-treatment symptoms,--planned according to the clinical case presentation verified by telephone contact, in COVID-19 negative patients but with referred symptoms related to radiation treatments.

According to institutional recommendations, the use of specific Personal Protective Equipment is indicated during treatments with an aerosol generating procedure such as intubation, open suctioning of the respiratory tract, endoluminal IRT with bronchoscopy or upper gastrointestinal endoscopy and IRT for some intrabuccal lesions [@b0005], [@b0040].

In these cases, it is suggested to wear disposable gloves, FFP2/FFP3 mask and fluid resistant surgical mask, eye/face protection, disposable fluid repellent gown, disposable caps and shoe covers.

The surgical room for IORT and the IRT dedicated room should have an area for donning and doffing of personal protective equipment and exchange of material and medications for the procedure.

In case of endocavitary and/or interstitial IRT requiring major anesthesia the definitive indication should be made considering the expected need for intensive therapy unit and its availability.

As long as IORT is concerned, cases should be prioritized by the Operating team and coordinated centrally [@b0045].

We suggest to shortening the case duration of surgery, discussing in advance every potential scenarios with the referring surgeons (e.g. treatment volume and doses according to site, histology and resection margins) and assigning the docking procedure to an expert team.

Optionally discuss treatment options in multidisciplinary boards with consultants from Anesthesia and Intensive Care and Infectious Diseases.

Patients should be adequately informed.

There are few evidences on the management of radiation treatments' long-term interruptions, due to large-scale emergencies [@b0050], [@b0055]. It is indicated to avoid or in any case limit delaying treatments that could negatively affect the disease control and/or the related symptoms, evaluating comorbidities and balancing the cost/benefit ratio related to infection or contamination risk and the risk of cancer not being treated optimally [@b0015], [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100].

Whenever possible and clinically indicated, providing radiotherapy and/or systemic therapy and/or targeted treatments would potentially reduce the impact on need for level 2/3 hospital beds for elective surgery. Patients over 70, especially with co-morbidities, are at highest risk of death from coronavirus and ideally, they should be seen once the pandemic is over, unless clinically urgent [@b0045].

[Table 2](#t0010){ref-type="table"} summarizes relevant clinical suggestions for COVID-19 negative or positive patients eligible for IRT treatments in relation to oncological disease.Table 2Relevant clinical indications for COVID-19 negative or positive patients eligible for IRT or IORT treatments. The indications should be decided on an individual basis.SitePatient settingInterruption impactCOVID− patientsCOVID+ patientsNotesBreast [@b0105], [@b0110], [@b0115]Low-risk AdjuvantMedium-lowConsider treatment omission in selected cases (age ≥ 70 years, invasive Luminal A, ≤2 cm, cN0, planned for endocrine therapy)\
PostponePostpone after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider exclusive IORT (if available)High-risk AdjuvantMedium-highPostpone limiting the time gapStart after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider IORT or perioperative IRT anticipated boost (if available) in particular for young patients (age ≤ 40 years as per EORTC trial).\
Evaluate concomitant boost if indicated (e.g. age ≤ 40 years, as per EORTC trial, or positive margins)Adjuvant salvage treatment for relapseHighStart ASAPPostpone after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider exclusive IORT or perioperative IRT (if available)\
Alternative EBRT or IRT (local anesthesia) with consequent no start-time limitationVulva-vagina [@b0120]AdjuvantLowPostpone if negative resection margins and cN0\
Consider omitting CT on case by case and resourcesPostpone after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy Pathway-CurativeHighStart ASAP\
Consider omitting CT on case by case and resourcesStart after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider EBRT if IRT requires major anesthesiaUterine cervix [@b0120]AdjuvantLowPostponePostpone--CurativeVery highStart ASAP\
Consider selected early stages that would normally undergo radical hysterectomy\
Consider omitting CT on case by case and resourcesStart ASAP if safety -- guaranteed\
Start after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider PDR or HDR IRT with bifractionated schemes to reduce hospitalization\
Consider to treat IR-CTV using EBRT in order to reduce the PDR time or the HDR fractions\
Consider smaller diameter applicators for better patient compliance and avoidance of anesthesia\
In experienced centres consider SBRT boost or SIB if IRT requires major anesthesia.\
Referral to another centre for IRT is generally preferred to using EBRTEndometrium [@b0120]AdjuvantIntermediate-lowObservation alone\
Postpone if high-risk up to 3 months from surgery unless residual disease, positive resection margins or aggressive histological subtypeObservation alone\
Postpone after confirmed healing if high-risk\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider strong hypofractionation\
Consider IRT only also in high-risk group on case by caseExclusiveIntermediate-highStart ASAP\
If surgery is not possible consider HT or CT (if locally advanced) on individualised situation.\
Consider EBRT and/or IRT in selected cases that would normally undergo radical hysterectomyPostpone after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider strong hypofractionationProstate [@b0030]Low riskVery lowConsider Surveillance or postponed treatmentConsider Surveillance or postponed treatmentConsider ultra-hypofractionated EBRTIntermediate/High riskHighConsider hypo fractionated EBRTPostpone decision after confirmed healing considering HTConsider EBRT boost instead of IRT boost\
Consider IRT only if resources are availablePenisCurativeMedium-highStart ASAPStart ASAP if safety -- guaranteed\
Start after confirmed healing\
Consider dedicated COVID19+ Radiotherapy PathwayConsider contact IRTUrethraPalliativeMedium-highStart ASAPStart ASAP if safety -- guaranteed\
Start after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider endoscopic desobstruction\
Consider single fraction HDR IRTTrachea and main bronchus [@b0125]PalliativeHighStart ASAPStart ASAP if safety -- guaranteed\
Start after confirmed healing\
Consider dedicated COVID19+ Radiotherapy PathwayConsider endoscopic desobstruction\
Consider single fraction HDR IRT or hypofractionated EBRTEsophagus [@b0130]CurativeHighStart ASAPStart ASAP after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider EBRT without IRT boost+/− CT\
If not suitable for concomitant CT, consider hypofractionated EBRT alonePalliativeHighStart ASAPStart ASAP only if safety-guaranteed\
Start after confirmed healingConsider stenting desobstruction\
Consider IRT or EBRT with single fraction or hypofractionated approachesBiliary ductPalliativeHighStart ASAPStart after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider stenting or external-drainage desobstructionAnal canal -- Lower Rectum [@b0135]CurativeMedium-highStart ASAP\
CT according to age, comorbidities and tumor biologyStart after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider EBRT if IRT requires major anesthesia\
Consider IORT anticipated boost (if available)\
If surgery not available, consider Short/Long course EBRT, on case by casePalliativeHighStart ASAPStart ASAP only if safety-guaranteed\
Start after confirmed healingConsider strong hypofractionation\
Consider IORT anticipated boost (if available)Skin [@b0140]AdjuvantLow/mediumChoice based on patient's prognosis, age, comorbidities and the location\
Consider postpone in case of basal cell carcinoma (outside face) even with closely excised margins\
Priority in case of squamous cell carcinoma and/or face locationPostpone after confirmed healingConsider hypofractionated regimensCurativeHigh/MediumSCC: No postponed, especially for large lesion or/and face lesion\
BCC: discuss in multidisciplinary board to postpone or contact ipofractionated radiotherapy based on lesion size and location (priority for face lesion)Discuss in multidisciplinary board if postpone or Contact ipofractionated radiotherapy\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider hypofractionated regimens\
Consider no biopsy but only clinical diagnosis)\
Consider in selected cases systemic therapy\
Priority in case of squamous cell carcinoma and/or palliative setting and/or face locationSoft tissues -- Sarcomas [@b0145]AdjuvantIntermediate -HighPostpone on an individual patient basisPostpone after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider IORT or perioperative IRT (if available)\
In selected cases, consider preoperative hypofractionated EBRT\
Consider hypofractionated IRT or EBRT with no start-time limitationLips -- Oral mucosaCurativeMedium-highStart ASAPStart ASAP only if safety -- guaranteed.\
Start after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayIRT (local-anesthesia)Tongue [@b0150]CurativeHighStart ASAPStart ASAP only if safety -- guaranteed.\
Start after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider switch to hypofractionated EBRT in order to avoid IRT with anesthesiologic involvement for bleeding riskNasopharynxCurativeHighStart ASAPStart ASAP only if safety -- guaranteed.\
Start after confirmed healing\
Consider dedicated COVID19+ Interventional Radiotherapy PathwayConsider hypo fractionated HDR IRT or EBRTKeloidsAdjuvantVery LowObservation alone\
Postpone\
Consider no surgery for benign diseaseObservation alone\
Postpone\
Consider no surgery for benign disease

By adopting these practical suggestions we will protect ourselves and the patients from the risk of infection, respecting oncological outcomes and reducing the workload in any Radiotherapy Service.

The indications reported in this orientation paper cannot leave aside the careful evaluation of the proposed treatment setting, the clinical case and the life expectancy of each patient also taking into account any concomitant or alternative valid therapy.
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